Investor List:

Top Therapeutics Series A Investors in San Francisco Bay Area (32)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Josh Wolfe, Managing Partner at Lux Capital
Josh Wolfe
Lux Capital·Managing Partner
Sweet spot: $10.0M
Range: $1M - $50.0M
Investors in New York (NY), Investors in Menlo Park (CA)
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of David Singer, Managing Partner at Maverick Capital
David Singer
Maverick Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Photo of Johnny Hu, Principal at Menlo Ventures
Johnny Hu
Menlo Ventures·Principal
Sweet spot: $12.0M
Range: $8.0M - $15.0M
Investors in SF Bay Area (CA), Investors in San Francisco (CA)
Photo of Robert Nelsen, Managing Director at ARCH Venture Partners
Robert Nelsen
ARCH Venture Partners·Managing Director
Sweet spot: $75.0M
Range: $50K - $150.0M
Investors in SF Bay Area (CA), Investors in Chicago (IL), Investors in Seattle (WA), Investors in Global
Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in AI (Seed), Investors in Wellness & Fitness (Seed), Investors in SaaS (Seed), Investors in SaaS (Seed), Investors in AI (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in AI (Seed), Investors in SaaS (Seed), Investors in AI (Seed), Investors in SaaS (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in AI (Series A), Investors in AI (Series A), Investors in SaaS (Series A), Investors in SaaS (Series A), Investors in Wellness & Fitness (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in SaaS (Series A), Investors in AI (Series A), Investors in SaaS (Series A), Investors in Seattle / Portland (Other Lists), Investors in Midwest (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Andres Carbonell, Investor at Plug & Play Ventures
Andres Carbonell
Sweet spot: $100
Range: $25 - $500
Investors in Sunnyvale (CA)
Investors in Drug Delivery (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in Drug Delivery (Seed), Investors in Pharmaceuticals (Seed), Investors in Medical Devices (Seed), Investors in Wellness & Fitness (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in Data Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Data Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Drug Delivery (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Wellness & Fitness (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in Data Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Data Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Anthony Goldbloom, Partner at AIX Ventures
Anthony Goldbloom
AIX Ventures·Partner
Sweet spot: $1M
Range: $500K - $2.0M
Investors in SF Bay Area (CA), Investors in Mountain View (CA)
Investors in Therapeutics (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Education (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Pre-seed), Investors in BioTech (Pre-seed), Investors in E-commerce (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Education (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in AI (Pre-seed), Investors in Health IT (Pre-seed), Investors in E-commerce (Pre-seed), Investors in AI (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Medical Devices (Seed), Investors in Generative Tech/AI (Seed), Investors in Generative Tech/AI (Seed), Investors in Medical Devices (Seed), Investors in Education (Seed), Investors in Digital Health (Seed), Investors in E-commerce (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Education (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in AI (Seed), Investors in BioTech (Seed), Investors in E-commerce (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in AI (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Medical Devices (Series A), Investors in Generative Tech/AI (Series A), Investors in Generative Tech/AI (Series A), Investors in Education (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in E-commerce (Series A), Investors in BioTech (Series A), Investors in Education (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series A), Investors in E-commerce (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in San Francisco Bay Area (Other Lists)
Photo of Jeffrey Bird, Managing Director at Bluebird Ventures
Jeffrey Bird
Bluebird Ventures·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Palo Alto (CA)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in San Francisco Bay Area (Other Lists)